Orphan Drug Clofarabine For Leukemia Patients

Orphan Drug

The FDA has granted marketing approval for clofarabine (Clolar™, Gen-zyme) to treat refractory or relapsed acute lymphoblastic leukemia (ALL) in children aged one to 21 years. This is the first new leukemia treatment approved specifically for children in more than a decade. The drug is approved for children who do not respond to initial therapy, who relapse, or whose prognosis for survival is poor.
discount drugs canda